Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis
Background: Progressive brain atrophy is a major feature of multiple sclerosis (MS) pathology and is actually considered a major determinant of the progressive accumulation of physical and cognitive disability in MS patients. Although brain atrophy may have different pathological substrates, several lines of evidence suggest that in disease modifying drug (DMD)-treated MS patients, the higher i...
متن کاملMultiple sclerosis and disease-modifying therapies.
Mia T. Minen, MD Steven Karceski, MD Over the past 18 years, treatments for multiple sclerosis (MS) called disease-modifying therapies (DMTs) have been developed. These therapies are designed to decrease the number of MS attacks, and to slow the progression of the disease. They have become a standard part of the current treatment for MS. There are different classes of the currently available DM...
متن کاملOral Disease-Modifying Therapies for Multiple Sclerosis
Classical multiple sclerosis (MS) treatments using first-line injectable drugs, although widely applied, remain a major concern in terms of therapeutic adherence and efficacy. New oral drugs recently approved for MS treatment represent significant advances in therapy. The oral route of administration clearly promotes patient satisfaction and increases therapeutic compliance. However, these drug...
متن کاملGray matter atrophy in multiple sclerosis: a longitudinal study.
OBJECTIVE To determine gray matter (GM) atrophy rates in multiple sclerosis (MS) patients at all stages of disease, and to identify predictors and clinical correlates of GM atrophy. METHODS MS patients and healthy control subjects were observed over 4 years with standardized magnetic resonance imaging (MRI) and neurological examinations. Whole-brain, GM, and white matter atrophy rates were ca...
متن کاملThe Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
INTRODUCTION The objective of this pilot study was to compare cerebral gray matter (GM) atrophy over 1 year in patients starting dimethyl fumarate (DMF) for multiple sclerosis (MS) to that of patients on no disease-modifying treatment (noDMT). DMF is an established therapy for relapsing-remitting (RR) MS. METHODS We retrospectively analyzed 20 patients with RRMS at the start of DMF [age (mean...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Multiple Sclerosis Journal
سال: 2019
ISSN: 1352-4585,1477-0970
DOI: 10.1177/1352458519826364